Galectin-3 (Gal-3) Inhibitors as Radiosensitizers for Prostate Cancer

We are pleased to announce the publication of the article “Galectin-3 (Gal-3) Inhibitors as Radiosensitizers for Prostate Cancer” by Renato M. Rodrigues, Bárbara Matos, Vera Miranda-Gonçalves, Carmen Jerónimo and Margarida Fardilha, published in Therapeutics (2026, 3(1), 7). 

In this study, we addressed radioresistance as a major therapeutic challenge in prostate cancer by investigating the role of Galectin-3 (Gal-3) and the impact of its pharmacological inhibition using GB1107 in parental and radioresistant prostate cancer cell models. This work results from a collaborative effort between Fardilha’s Lab (iBiMED, University of Aveiro) and the Portuguese Oncology Institute of Porto, reinforcing the importance of translational research in prostate cancer. 

Read more here 👇

https://lnkd.in/eUn2jcGZ